Pharmaceutical US clinical-stage biopharma Apollomics (Nasdaq: APLM) leapt on the announcement yesterday that its partner in China, Avistone Biotechnology, has received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). 17 November 2023